{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:14:18Z","timestamp":1795029258025,"version":"4.10.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Project of Guangzhou City","award":["202201011375"],"award-info":[{"award-number":["202201011375"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04110-1","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:09:19Z","timestamp":1746799759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Lujun","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulijiayina","family":"Nuerhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hontong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanggang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"3","key":"4110_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4110_CR2","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236."},{"issue":"9822","key":"4110_CR3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245\u201355.","journal-title":"Lancet"},{"issue":"1","key":"4110_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4110_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"key":"4110_CR6","doi-asserted-by":"crossref","unstructured":"Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7(3):235\u201360.","DOI":"10.1159\/000488035"},{"issue":"1","key":"4110_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s13046-019-1412-8","volume":"38","author":"Z Liu","year":"2019","unstructured":"Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):447.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"4110_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953\u201360.","journal-title":"JAMA Oncol"},{"key":"4110_CR9","doi-asserted-by":"publisher","first-page":"5825401","DOI":"10.1155\/2020\/5825401","volume":"2020","author":"Y Igarashi","year":"2020","unstructured":"Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res. 2020;2020:5825401.","journal-title":"J Immunol Res"},{"key":"4110_CR10","doi-asserted-by":"publisher","first-page":"1127349","DOI":"10.3389\/fimmu.2023.1127349","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, Zhang K, Liu C, Gao W, Si T, Zou Q, et al. Hepatic arterial infusion chemotherapy combined with anti-PD-1\/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. Front Immunol. 2023;14:1127349.","journal-title":"Front Immunol"},{"key":"4110_CR11","doi-asserted-by":"crossref","unstructured":"Xu JM, Zhang Y, Jia R, Yue CY, Chang L, Liu RR, et al. Anti-PD-1 Antibody SHR-1210 combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.\u00a0Clin Cancer Res. 2018.","DOI":"10.1158\/1078-0432.CCR-18-2484"},{"key":"4110_CR12","doi-asserted-by":"crossref","unstructured":"Shen L, Qi H, Chen S, Cao F, Xie L, Wu Y, et al. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Cancer Immunol Immunother. 2020.","DOI":"10.1007\/s00262-020-02566-z"},{"key":"4110_CR13","doi-asserted-by":"crossref","unstructured":"Qianqi C, Yan Z, Yueqiang T, Jiangman D, Xiaohong F, Qiming Z. Efficacy and safety of transarterial infusion of anti-PD-1 in the treatment of advanced or metastatic acral and mucosal melanomas. Cell Mol Biol (Noisy-le-grand). 2022;67(5):263\u20138.","DOI":"10.14715\/cmb\/2021.67.5.36"},{"issue":"1","key":"4110_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"key":"4110_CR15","doi-asserted-by":"crossref","unstructured":"Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67(5):1025\u201339.","DOI":"10.1016\/j.jaad.2012.02.010"},{"issue":"1","key":"4110_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"issue":"1","key":"4110_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Hepatocellular carcinoma Nat Rev Dis Primers"},{"issue":"1","key":"4110_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023;8(1):413.","journal-title":"Signal Transduct Target Ther"},{"issue":"10408","key":"4110_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"issue":"1","key":"4110_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12885-022-09173-4","volume":"22","author":"SC Chen","year":"2022","unstructured":"Chen SC, Huang YH, Chen MH, Hung YP, Lee RC, Shao YY, et al. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer. 2022;22(1):55.","journal-title":"BMC Cancer"},{"key":"4110_CR21","doi-asserted-by":"publisher","first-page":"1383456","DOI":"10.3389\/fimmu.2024.1383456","volume":"15","author":"SA Javed","year":"2024","unstructured":"Javed SA, Najmi A, Ahsan W, Zoghebi K. Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Front Immunol. 2024;15:1383456.","journal-title":"Front Immunol"},{"issue":"9","key":"4110_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"10","key":"4110_CR23","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205.","journal-title":"Immunity"},{"issue":"1","key":"4110_CR24","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2024.100052","volume":"2","author":"X Zhou","year":"2024","unstructured":"Zhou X, Zhang B, Hu J, Shen J, Chen Z, Zhang J, et al. Igniting cold tumors of intrahepatic cholangiocarcinoma: an insight into immune evasion and tumor immune microenvironment. Innov Med. 2024;2(1): 100052.","journal-title":"Innov Med"},{"issue":"3","key":"4110_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","volume":"15","author":"Q Gao","year":"2009","unstructured":"Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4110_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"key":"4110_CR27","doi-asserted-by":"crossref","unstructured":"Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020;5(52).","DOI":"10.1126\/sciimmunol.aba0759"},{"issue":"2","key":"4110_CR28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506\u201315.","journal-title":"J Hepatol"},{"issue":"Pt A","key":"4110_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111019","volume":"125","author":"M Zang","year":"2023","unstructured":"Zang M, Hu X, Yuan G, Li R, Li W, Pang H, et al. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: a retrospective study. Int Immunopharmacol. 2023;125(Pt A): 111019.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4110_CR30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023;109(5):1222\u201330.","journal-title":"Int J Surg"},{"key":"4110_CR31","doi-asserted-by":"publisher","unstructured":"Shen L, Jiang Y, Lu L, et al. Dynamic prognostication and treatment planning for hepatocellular carcinoma: A machine learning-enhanced survival study using multi-centric data.\u00a0Innov Med. 2025;3:100125. https:\/\/doi.org\/10.59717\/j.xinn-med.2025.100125.","DOI":"10.59717\/j.xinn-med.2025.100125"},{"key":"4110_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377.","journal-title":"Eur J Cancer"},{"issue":"6","key":"4110_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.4149\/neo_2023_230806N413","volume":"70","author":"D Liu","year":"2023","unstructured":"Liu D, Mu H, Liu C, Zhang W, Cui Y, Wu Q, et al. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial. Neoplasma. 2023;70(6):811\u20138.","journal-title":"Neoplasma"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04110-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:09:25Z","timestamp":1746799765000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4110"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04110-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the trial was granted by the Institutional Review Board of the Sun Yat-sen University Cancer Center (B2020-230\u201301). All participants provided written consent to be involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}